REGENXBIO reported positive 3-year Phase II data for investigational sura vec in diabetic retinopathy, adding evidence of the therapy’s durability. ALTITUDE study results were presented at the Retina Society meeting.
published
REGENXBIO reported positive 3-year Phase II data for investigational sura vec in diabetic retinopathy, adding evidence of the therapy’s durability. ALTITUDE study results were presented at the Retina Society meeting.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.